CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胃肠道肿瘤中的新型 Claudin18.2 靶向治疗
英文原题：Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors.
查看英文原题
Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胃肠道（GI）肿瘤是一类发病率和致死率不断上升的恶性肿瘤，因此亟需探索更具特异性的治疗靶点。近期，黏附蛋白claudin 18.2（CLDN18.2）成为拓展GI肿瘤靶向治疗范围的有希望靶点，因为其可通过调节PI3K-AKT和RAF-MAPK信号通路及肿瘤微环境，促进肿瘤细胞增殖和逃逸。CLDN18.2靶向疗法取得了显著进展，推动了对新联合方案以及利用纳米颗粒和CAR-T 改造药物的CLDN18.2靶向治疗的研究。充分理由支持优先研究CLDN18.2在GI肿瘤中的意义。CLDN18.2独特的表达特征使其成为开发精准指导型GI肿瘤治疗干预的有前景生物标志物。
展开英文摘要原文
Gastrointestinal (GI) tumors are a type of malignant tumor characterized by their increasing incidence and lethality.
Thus, there is an urgent need to explore more peculiar treatment targets. Recently, the adhesion protein claudin18. 2 (CLDN18. 2) has emerged as a promising target for expanding the scope of targeted therapy for GI tumors because it facilitates the proliferation and evasion of tumor cells through mediation of PI3K-AKT and RAF-MAPK signaling pathways and tumor microenvironment. Therapies targeting CLDN18.
2 have advanced considerably, prompting research into new combination regimens and modified CLDN18. 2 targeted drug using nanoparticles and CAR-T-modified drugs. There is a compelling rationale to prioritize the investigation of the significance of CLDN18. 2 in GI tumors. The unique expression of CLDN18. 2 renders it as a promising biomarker for developing precision-guided therapeutic interventions for GI tumors.
论文信息
- 作者
- Ye W、Xu M、Gu Y、Ou WB
- 单位
- Department of Biopharmaceutics, Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.China
- 文献类型
- 综述
- 期刊
- ACS omega2025 Sep 16
- 原文标识
- PubMed 40978415 · DOI 10.1021/acsomega.5c06506
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →